We are live on ! Find out more

Rapport Therapeutics

RAPP

Market cap $1.46B

25.93 USD

+0.49

1.93%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

25.91

-0.02

0.08%

1 day

1.93%

5 days

14.84%

1 month

-19.45%

3 months

-38.55%

6 months

-27.02%

Year to date

-7.76%

1 year

-2.7%

5 years

24.66%

10 years

24.66%

About: Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Employees: 84

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35%

Neutral 60%

Negative 5%

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q 2026; Phase 3 FOS trials enrolling patients Well-capitalized with $815.4 million1 in cash and cash equivalents as of November 3, 2026, and runway through the end of 2029 BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including a summary of the recently announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania and updates across the RAP-219 development program and pipeline. “We continue to deliver on our priorities with strong execution across the portfolio,” said Abraham N.

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference (New York City, NY) Fireside chat on Wednesday, November 11, 2026, at 1:20 – 1:50 p.m.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the closing of its previously announced separate underwritten public offerings of 9,761,905 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase up to 1,428,571 additional shares of its common stock, at a public offering price of $21.00 per share (the “Offering Price”) and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to 1,190,476 shares of its common stock at an offering price of $20.999 per pre-funded warrant, which represents the per share Offering Price less the $0.001 per share exercise price for each pre-funded warrant (the “common stock offering”) and $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032 (the “notes”), which includes the exercise in full of the underwriters' over-allotment option to purchase up to an additional $22.5 million aggregate principal amount of notes (the “notes offering” and together with the common stock offering, the “underwritten offerings”). Concurrently with the underwritten offerings, Rapport entered into a securities purchase agreement with a certain investor (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport sold to the Investor 1,428,571 shares of Rapport's common stock, at the Offering Price.

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of separate underwritten public offerings of approximately $175.0 million of shares of its common stock at an offering price of $21.00 per share (the “Offering Price”) and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to approximately $25.0 million of shares of its common stock at an offering price of $20.999 per pre-funded warrant, which represents the per share Offering Price less the $0.001 per share exercise price for each pre-funded warrant (the “common stock offering”) and $150.0 million aggregate principal amount of 2.25% convertible senior notes due 2032 (the “notes”) (the “notes offering” and together with the common stock offering, the “underwritten offerings”). Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport agreed to offer and sell, and the Investor agreed to purchase, approximately $30.0 million of shares of Rapport's common stock, at the Offering Price. The sale of shares to the Investor in the concurrent private placement will not be registered as part of the common stock offering.

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced separate underwritten public offerings of $200.0 million of shares of its common stock (the “common stock offering”) and $150.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes offering” and together with the common stock offering, the “underwritten offerings”). In addition, Rapport intends to grant the underwriters in the common stock offering a 30-day option to purchase up to an additional $30.0 million of shares of its common stock under the same terms and conditions and intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of notes solely to cover over-allotments, if any. Concurrently with the underwritten offerings, Rapport intends to enter into a share purchase agreement with a certain investor named therein (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport intends to offer and sell, and the Investor intends to purchase shares of Rapport's common stock at the price per share of common stock in the common stock offering. The sale of shares to the Investor in the proposed concurrent private placement will not be registered as part of the common stock offering. The proposed offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into Phase III development.

Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Why Is Rapport Therapeutics Stock Trading Higher Today?

Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data.

Why Is Rapport Therapeutics Stock Trading Higher Today?

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

Investors Business Daily

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher

Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher

See News Rankings

Price charts implemented using Lightweight Charts™